Novartis Pauses Autoimmune Cell Therapy Trials Following Patient Deaths

Novartis has suspended multiple clinical studies of its experimental CAR-T cell therapies for autoimmune diseases after three patients died during treatment. The company is conducting a thorough safety review before determining whether to resume or modify the trials.